Atlas Capital Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Atlas Capital Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-348	Closed	-$14.8K	–	923
2022 Q3	$14.8K	Buy	+348	New	+$17.8K	﹤0.01%	685
2022 Q2	–	Sell	-348	Closed	-$21.6K	–	991
2022 Q1	$21.6K	Hold	348	–	–	﹤0.01%	629
2021 Q4	$19.2K	Sell	348 -700	-67%	-$36.5K	﹤0.01%	641
2021 Q3	$55.1K	Hold	1,048	–	–	0.01%	508
2021 Q2	$72.2K	Buy	1,048 +700	+201%	+$53.4K	0.01%	491
2021 Q1	$26.8K	Sell	348 -533	-60%	-$49.1K	0.01%	560
2020 Q4	$87.2K	Buy	+881	New	+$108K	0.02%	411

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Atlas Capital Advisors's LKFT Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 348 shares — an estimated $14.8K sold.

Atlas Capital Advisors first reported a position in LKFT in Q4 2020 and held it in 7 quarters. The position peaked at $87.2K in Q4 2020. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

Atlas Capital Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Atlas Capital Advisors sold 348 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $14.8K.
Atlas Capital Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 7 quarters.
Atlas Capital Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $87.2K in Q4 2020.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.